Antra

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antra

Property Description
Active ingredient Omeprazole (INN)
Form Delayed-release capsule / Enteric-coated tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid
Origin Synthetic (Substituted Benzimidazole)

What is Antra?

Antra is a synthetic, single-ingredient medicinal entity whose active substance is Omeprazole, chemically classified as a substituted benzimidazole. As a member of the Proton Pump Inhibitor (PPI) pharmacological class, its foundational purpose is to achieve profound and sustained reduction of acidity within the stomach.


What Type of Medicine is Antra and What is its Composition?

Antra is defined by its active ingredient, Omeprazole (INN), a synthetic compound that acts as a potent Gastric Acid Secretion Inhibitor. This compound is engineered to directly target and irreversibly inhibit the proton pump (H+/K+-ATPase), which is the final enzymatic step necessary for the gastric parietal cells to produce acid. The Omeprazole molecule, which can be formulated as a free acid, magnesium salt, or sodium salt, is clinically recognized for providing a highly specific and enduring blockade of the acid production pathway, differentiating it fundamentally from earlier acid-controlling agents.


How Does Antra Work to Control Stomach Acid?

The medicine functions by causing a sustained decrease in both basal and stimulated acid secretion, which is its core general purpose. Omeprazole's classification as a PPI means it is one of the most effective compounds for reducing gastric acid output within pharmacological classification. This action results in the medicine creating a controlled, non-acidic environment within the stomach. This effective chemical suppression alleviates the damaging stress on the mucosal lining, supporting the body's natural healing processes for tissues compromised by chronic acid exposure.


What are the Available Forms of Omeprazole?

Omeprazole is presented in several pharmaceutical preparations to ensure its efficacy, primarily including the delayed-release capsule and the enteric-coated tablet, which are designed for oral intake. The critical feature of these forms is the specialized enteric coating, which protects the acid-labile Omeprazole from being destroyed by stomach acid, ensuring it reaches the small intestine for absorption. Furthermore, Omeprazole is available as a powder for injection for intravenous administration when the oral route is clinically impractical.

Regulatory References

  1. Omeprazole: MedlinePlus Drug Information

What side effects are possible with Antra?

Possible side effects and safety information

The official safety profile for omeprazole is structured by adverse reactions classified according to their documented frequency and affected physiological systems. Adverse reactions are classified based on regulatory criteria, such as the EMA and FDA standards.

Common Adverse Reactions (Frequently Documented)

The most commonly reported adverse reactions include headache and various gastrointestinal disturbances such as abdominal pain, nausea, diarrhea, vomiting, and flatulence. Uncommon reactions, documented in official labeling, include insomnia, dizziness, increased liver enzymes, and skin reactions such as rash or pruritus.

Serious Adverse Reactions and Regulatory Safety Concerns

Specific serious adverse reactions that are rarely documented include Acute Tubulointerstitial Nephritis (AIN), a hypersensitivity reaction that can affect the kidneys, and Severe Cutaneous Adverse Reactions (SCARs), such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Other documented safety concerns include the risk of hypomagnesemia (low magnesium levels) and an increased risk of bone fracture involving the hip, wrist, or spine.

Safety Patterns Related to Duration of Use

The prescribing information notes that certain risks are associated with long-term, continuous daily use. For example, use over several years may be linked to an increased risk of developing fundic gland polyps or Cyanocobalamin (Vitamin B-12) deficiency. Furthermore, the safety documentation includes the high-level constraint that a symptomatic response to treatment does not exclude the possibility of an underlying gastric malignancy.

Population-Specific Safety Notes

The safety profile for pediatric patients is generally similar to that of adults, although respiratory system events and fever have been noted more frequently in pediatric studies. Caution is noted for patients with hepatic impairment due to potential changes in drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information for Omeprazole (Antra) outlines the specific clinical manifestations that may occur in cases of overdosage, which have been reported following the ingestion of doses up to 900 mg.

Documented Overdose Manifestations
Common Signs Confusion, Drowsiness, Headache, Nausea, Dry mouth
Autonomic/Cardiovascular Tachycardia (fast heart rate), Flushing, Diaphoresis (sweating)
Other Blurred vision

In most reported cases involving high-dose ingestion, the observed symptoms were generally transient, and regulatory authorities have noted that no serious clinical outcome has been confirmed.

Required Emergency Actions

It is officially mandated to get medical help or contact a Poison Control Center right away if an overdose is suspected. Urgent medical attention is required, and emergency services must be contacted immediately if the affected individual exhibits specific life-threatening clinical events, including seizure, collapse, trouble breathing, or the inability to be awakened. Management of an overdosage is symptomatic and supportive. The official guidance confirms that no specific antidote is known for Omeprazole. Since the drug is extensively protein bound, it is also not readily removed by dialysis.

Therapeutic Uses of Antra

What Antra treats: main uses and benefits

Antra is a medication belonging to the class of proton pump inhibitors (PPIs). Its primary function is to reduce the production of acid in the stomach by inhibiting the enzyme system responsible for the final step of acid secretion. This reduction in gastric acidity helps in the healing of damaged tissues and the management of conditions related to excessive acid.

Principal Applications

Antra is utilized in the management of several gastrointestinal conditions where acid reduction is necessary for symptom relief or tissue recovery:

  • Gastroesophageal Reflux Disease (GERD): It is used to treat symptoms such as heartburn and acid regurgitation caused by the backflow of stomach acid into the esophagus. It also facilitates the healing of erosive esophagitis, which is inflammation or sores in the esophageal lining.
  • Peptic Ulcers: The medication is used to treat and prevent the recurrence of ulcers in the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers).
  • NSAID-Associated Ulcers: It is used to treat ulcers that may develop as a result of taking non-steroidal anti-inflammatory drugs (NSAIDs) and may be prescribed as a preventive measure for patients at risk who require ongoing NSAID therapy.
  • Helicobacter pylori Eradication: In combination with appropriate antibiotics, Antra is used to eliminate H. pylori bacteria, a common cause of recurring peptic ulcers.
  • Zollinger-Ellison Syndrome: It is indicated for the management of pathological hypersecretory conditions, where the stomach produces extreme amounts of acid.

Benefits of Treatment

By effectively lowering the level of acidity in the digestive tract, Antra provides several therapeutic benefits:

  • Symptom Relief: Significant reduction in the frequency and severity of acid-related discomfort, such as burning sensations in the chest and upper abdomen.
  • Tissue Healing: Provides an environment that allows the lining of the stomach and esophagus to repair itself from acid-induced damage and inflammation.
  • Prevention of Complications: Long-term management can help prevent serious complications associated with chronic acid reflux or untreated ulcers, such as narrowing of the esophagus or gastrointestinal bleeding.

Regulatory References

  1. NIH MedlinePlus omeprazole guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Antra (Omeprazole)

Antra is defined by official regulatory documents as having strict population eligibility rules. Use is contraindicated for patients with a known hypersensitivity to omeprazole, to other substituted benzimidazoles, or to any component of the formulation. The medicine must also not be used concurrently with certain antiviral drugs, such as nelfinavir or rilpivirine, as this is prohibited by regulatory bodies.

Age-Related and Conditional Eligibility

Age Group Eligibility Status
Adults (18+ years) Established use for all labeled indications.
Children ge 1 year Established use for symptomatic GERD and erosive esophagitis.
Infants < 1 month Safety and effectiveness have not been established for most uses.

Patients with severe hepatic impairment are flagged for restricted use, often requiring a lower maximum daily dose. For pregnancy and lactation, use is not recommended unless the potential benefit is determined to outweigh the risk, as the drug is secreted in human milk. Additionally, gastric malignancy must be excluded before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Antra (Omeprazole) has officially documented interaction patterns primarily driven by its effect on gastric pH and its role as an inhibitor of the CYP2 C19 enzyme. All stated interactions are based on official government regulatory documents.

Regulatory Prohibitions and Restrictions

Co-administration is officially advised to be avoided or is not recommended with several key medicines. This includes Clopidogrel, due to a diminished anti-platelet effect, and the antiretrovirals Atazanavir and Nelfinavir, due to substantially reduced plasma concentrations of the latter agents. Co-administration with the CYP2 C19 and CYP3 A4 inducers Rifampin and St John's Wort is also advised to be avoided due to the potential for reduced Omeprazole exposure.

Pharmacokinetic and Pharmacodynamic Effects

Omeprazole alters the absorption and systemic exposure of many co-administered substances. The reduction in stomach acid may decrease the absorption of medicines such as Ketoconazole and Iron salts but may increase the absorption and plasma levels of Digoxin. Its inhibition of CYP2 C19 may prolong the elimination of drugs including Diazepam, Phenytoin, and Warfarin. Increased exposure has also been documented for medicines like Cilostazol, Tacrolimus, and Saquinavir.

Timing and Population Considerations

A mandatory timing restriction requires treatment cessation at least 14 days prior to certain neuroendocrine diagnostic tests, such as Chromogranin A (CgA). For specific populations, individuals identified as CYP2 C19 Poor Metabolizers exhibit higher systemic exposure to Omeprazole. Additionally, long-term daily use is associated with a risk of reduced Vitamin B12 absorption.

Mechanism of Action

The Mechanism of Antra: PPARalpha Agonism

Antra (fenofibrate) exerts its action through its active metabolite, fenofibric acid, which functions as a selective agonist for the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha). This nuclear receptor is found predominantly in the liver and cells highly involved in lipid metabolism.

Binding to PPARalpha initiates a transcriptional cascade that alters gene expression. Specifically, it increases the synthesis of Lipoprotein Lipase (LPL), an enzyme critical for breaking down triglycerides in the blood. Concurrently, it represses the production of Apoprotein C-III (ApoC-III), which normally inhibits LPL activity.

This molecular adjustment results in the accelerated catabolism and clearance of triglyceride-rich lipoprotein particles, such as VLDL and chylomicrons, from the plasma. The resulting physiological consequence is a reduction in plasma triglyceride concentrations and an increase in HDL-cholesterol levels, altering the systemic lipid profile.

Dosage and Administration Information

How to use Antra

The administration of Antra (Omeprazole) involves specific procedures for proper use. The primary route of administration is oral, utilizing forms such as delayed-release capsules, tablets, or powder for suspension. An intravenous (IV) route is used for temporary periods in hospital settings when oral intake is clinically impracticable.

Standard adult dosing regimens are typically 20 mg or 40 mg administered once daily for most short-term treatments, including healing ulcers and erosive esophagitis. For pathological hypersecretory conditions, initial dosing is often 60 mg once daily, with the total dose adjusted up to 360 mg per day; doses exceeding 80 mg must be divided for proper scheduling.

Administration Timing is a critical procedural condition: the medication should be taken before a meal, ideally in the morning. The delayed-release integrity of the oral forms must be strictly maintained; therefore, capsules and tablets must be swallowed whole and must not be crushed or chewed to protect the active ingredient. For patients unable to swallow, the capsule pellets may be mixed with a small amount of soft food, such as applesauce, and swallowed immediately.

Treatment is typically provided in short-term courses of 4 to 8 weeks. Dose reduction should be considered in individuals with severe hepatic impairment, but generally no specific adjustment is required for renal impairment or in older adults. If a dose is missed, it is taken as soon as remembered unless it is nearly time for the next scheduled dose, in which case the regular schedule is resumed without doubling the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Antra (Omeprazole)


Evidence for Healing and Managing Acid Reflux Disease (GERD and Erosive Esophagitis)

Clinical research for Omeprazole has often relied on short-term Randomized Controlled Trials (RCTs) and systematic reviews exploring its role in the short-term assessment of change in GERD symptoms and the acute evaluation of repair of physical damage (erosive esophagitis). For GERD, studies primarily focused on outcomes related to physical discomfort, examining how symptoms change over defined time intervals. Findings describe how symptoms evolved in the observed populations over periods such as two to four weeks.

For Erosive Esophagitis, studies monitored the repair of physical lesions. Upon evaluation of initial repair, further long-term RCTs, typically lasting six to twelve months, were conducted to explore the duration of that repair and monitor recurrence rates. The measurements described for acute repair and maintenance were the subject of multiple peer-reviewed analyses. Follow-up durations were limited in many controlled trials, meaning long-term outcomes beyond one year are not as fully established.


Evidence for Treating Ulcers and Addressing the H. pylori Bacteria

Omeprazole was evaluated in studies focused on the acute management of ulcers located in the stomach and the duodenum. Research examined clinical outcomes such as the repair rate of the ulcers and patient-reported outcomes describing perceived discomfort. Omeprazole was studied for use as a component of specific multi-drug combination regimens with antibiotics for H. pylori eradication. Studies monitored the H. pylori eradication rate and explored the subsequent outcomes related to monitoring the risk of ulcer recurrence in patients where eradication was confirmed. Evidence is limited regarding the stability of eradication rates across different global regions, as results can vary based on local antibiotic resistance patterns.


Evidence in Specific Patient Populations

Omeprazole was evaluated in studies involving specific age groups, primarily pediatric patients, for the management of Erosive Esophagitis. While this research provides context, the availability of data for certain groups is limited. For instance, certain comorbidity-defined groups have not been as comprehensively studied as the general adult population. Results apply only to the populations studied, and researchers recommend that findings describe group patterns, not personal outcomes, for individuals outside these studied cohorts.

Frequently Asked Questions (FAQ)

Common questions about Antra (FAQ)

Q: What is the main reason doctors prescribe Antra?

Regulatory documents state that Omeprazole (the active ingredient in Antra) is officially approved to treat conditions caused by excess stomach acid. These include Gastroesophageal Reflux Disease (GERD), the healing and maintenance of erosive esophagitis, the management of duodenal and gastric ulcers, and a condition called Zollinger-Ellison syndrome.

Q: How does Antra compare generally to other medicines used for the same condition?

Antra belongs to the class of Proton Pump Inhibitors (PPIs). This class of medicine is differentiated from older acid-reducing agents by its mechanism: it directly blocks the final step of acid production in the stomach. Official information indicates that this results in a sustained reduction in stomach acid.

Q: How long after starting Antra should I expect to notice any change?

According to official product information, the acid-blocking effects of the medication begin relatively quickly, often within about an hour of administration. However, for over-the-counter use, the labeling advises that it may take one to four days for the full effects to be noticeable in symptom relief.

Q: Is Antra safe for teenagers to use?

The official product information supports the use of Omeprazole in pediatric patients for certain conditions, including GERD and erosive esophagitis. Regulatory documents state that use in pediatric populations requires consideration of the specific condition and patient's weight.

Q: What is the risk of an allergic reaction to Antra?

The medicine is contraindicated (must not be used) if a person has a known hypersensitivity or allergy to Omeprazole or similar medicines. Regulatory warnings note the rare possibility of serious hypersensitivity reactions, including severe skin reactions like SCARs and a kidney condition called AIN.

Q: What is the general success rate mentioned in Antra's clinical trials?

Studies and official information indicate that Omeprazole clinical trials report high rates of healing for both erosive esophagitis and ulcers, typically occurring within four to eight weeks of treatment. Studies also describe favorable outcomes for H. pylori eradication when Omeprazole is used as a component of specific multi-drug regimens with antibiotics.

Q: What does 'contraindication' mean for Antra in simple terms?

A contraindication describes a circumstance or pre-existing condition that regulatory agencies state is a restriction against using the medicine. For Antra, this restriction applies to conditions like allergies to the medicine or concurrent use with certain antiviral medications like nelfinavir or rilpivirine.

Q: What is the difference between Antra and its generic counterpart, if one exists?

The active ingredient in the brand-name product Antra is Omeprazole. A generic counterpart contains the exact same active ingredient and must meet the same strict standards for quality, strength, purity, and effectiveness as the brand-name product.

Q: Is Antra considered a pain reliever or something else?

Official information defines Omeprazole as a Proton Pump Inhibitor (PPI). Its function is to work directly in the stomach to reduce the production of acid. It is not classified as a traditional pain reliever (analgesic).

Q: Can I take Antra if I am already taking over-the-counter vitamins?

Long-term daily use of Omeprazole is documented in official warnings as being associated with a potential for reduced absorption of Vitamin B12. Additionally, its acid-reducing effect may interfere with the absorption of other substances, such as Iron salts, though no broad warnings exist for all general vitamins.

Q: Is feeling more tired a common issue when starting Antra?

While insomnia (difficulty sleeping) is listed as an uncommon side effect in regulatory documents, overall fatigue or tiredness is generally not cited as a frequently reported adverse reaction. This information is based on the frequencies observed during clinical studies.

Q: Are there any specific foods or drinks to avoid while taking Antra?

Official administration instructions emphasize that the delayed-release forms must be swallowed whole and taken before a meal. Regulatory documents do not specify the prohibition of common foods or drinks.

Q: Is it true that Antra interacts with blood pressure medication?

Official regulatory documents list interactions with certain cardiovascular medicines. For example, Omeprazole can increase the systemic exposure of Digoxin, a medicine used to treat heart failure. Co-administration with Diuretics (a type of blood pressure medicine) should be considered carefully due to the potential risk of low magnesium levels.

Q: What happens if I stop taking Antra suddenly?

Clinical studies suggest that discontinuing Omeprazole, particularly after long-term use, can lead to a condition called rebound acid hypersecretion. This means acid production temporarily increases above the level it was at before treatment, which can cause a return or worsening of acid-related symptoms.

Q: Are there any warnings about driving or operating machinery while on Antra?

Regulatory documents list dizziness as an uncommon adverse reaction. Therefore, individuals experiencing this or other central nervous system effects may need to consider the impact on activities such as driving or operating machinery.

Q: Are there known issues with Antra and sun exposure?

Regulatory warnings mention the potential risk of developing or worsening a condition called Lupus Erythematosus, an inflammatory condition. Regulatory documents describe a potential risk of developing or worsening a condition that involves a rash on the cheeks or arms that gets worse after sun exposure.

Q: Is the severity of side effects from Antra usually dose-dependent?

Official clinical pharmacology information indicates that the acid-inhibiting effect is dose-dependent. While the severity of all side effects is not explicitly linked to dose, regulatory warnings associate risks like bone fracture and certain deficiencies with higher doses and prolonged use.

Q: Do experts recommend taking Antra at the same time every day?

The official administration instructions indicate that Omeprazole is generally prescribed to be taken once daily, before a meal, and ideally in the morning. Taking the dose at a consistent time is important for maintaining effective acid control, as described in official documents.

Q: Do studies suggest Antra works better for certain groups of people?

Yes, official pharmacokinetics data indicates that the body processes the drug differently in certain groups. Individuals identified as CYP2C19 Poor Metabolizers show significantly higher systemic exposure to Omeprazole than other individuals, which may alter the effect of the drug in this specific population.

Q: How long does Antra typically stay in your system after stopping?

The active substance, Omeprazole, has an elimination half-life of approximately 0.5 to 1 hour. However, its pharmacological effect (the profound acid suppression) lasts significantly longer than the drug is detectable in the blood due to its irreversible binding to the proton pump.

Q: Why does the packaging for Antra have a specific black box warning?

Official regulatory documents indicate that Omeprazole does not carry a Black Box Warning, which is the strongest type of warning required by the FDA. While warnings for serious risks, such as bone fracture and low magnesium, are present, they are detailed in the standard 'Warnings and Precautions' section.

How should Antra be stored and disposed of?

How to Store and Dispose of Antra (Omeprazole)

Official regulatory information requires Antra to be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and light and should be kept in the original, tightly closed container until use. This helps preserve the product's stability and efficacy.

Stability and Handling Constraints:

  • Do not crush or chew the delayed-release granules.
  • Any prepared suspension must be swallowed immediately and not stored for future use.

Disposal Requirements:

To protect the environment, unused or expired Antra must not be disposed of in household trash or poured down a sink or toilet. Medicine should be disposed of in accordance with local regulations, often by utilizing a designated drug take-back program or returning it to a pharmacy. Always keep the medicine out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antra found in:

A-Z Index: